What is iRadimed's stock-based comp?

iRadimed (IRMD) reported stock-based comp of $684K in Q1 2026.

How has iRadimed's stock-based comp changed year-over-year?

iRadimed's stock-based comp decreased by 17.2% year-over-year, from $826K to $684K.

What is the long-term trend for iRadimed's stock-based comp?

Over 4 years (2021 to 2025), iRadimed's stock-based comp has grown at a 17.8% compound annual growth rate (CAGR), from $1.52M to $2.92M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

iRadimed IRMD Stock-Based Comp

Stock-Based Comp at other companies

GE HealthCare TechnologiesGEHC

$35M+59.1%

Merit Medical SystemsMMSI

$8.96M-1.3%

ICU MedicalICUI

$14.01M+15.0%

ITG

Integer HoldingsITGR

$6.66M-3.2%

Lumexa Imaging Holdings, Inc. LMRI

$12.27M+92.6%

RadNetRDNT

$31.38M+10.1%

Other financials

Income statement

See full

Revenue$22.0M+12.6%

Gross profit$16.8M+13.3%

Operating income$7.2M+33.2%

Net income$5.8M+24.1%

EPS (diluted)$0.45+21.6%

Balance sheet

See full

Cash & equivalents$56.4M+12.0%

Total debt$59.2K-96.9%

Total equity$98.5M+9.4%

Total assets$114.4M+12.4%

Cash flow

See full

Operating cash flow$8.3M+93.2%

CapEx$403.0K-89.1%

Free cash flow$7.9M+1,226%

Valuation

See full

Market cap$1.21B+63.4%

P/E51.3×+13.8×

P/S14×+4.2×

Profitability

See full

Gross margin76.8%-0.1pp

Operating margin32.4%+2.3pp

Net margin27.4%+1.0pp

FCF margin28.4%+8.9pp

Returns & leverage

See full

Return on equity25%+1.2pp

Debt / equity0×0.0×

Current ratio7.1×-1.7×

Where this comes from

Reported directly by iRadimed in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: iRadimed’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about iRadimed's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is iRadimed's stock-based comp?: iRadimed (IRMD) reported stock-based comp of $684K in Q1 2026.
How has iRadimed's stock-based comp changed year-over-year?: iRadimed's stock-based comp decreased by 17.2% year-over-year, from $826K to $684K.
What is the long-term trend for iRadimed's stock-based comp?: Over 4 years (2021 to 2025), iRadimed's stock-based comp has grown at a 17.8% compound annual growth rate (CAGR), from $1.52M to $2.92M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.